Oncoinvent
Less than 1K followers
ONCIN
Euronext Growth Oslo
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.
Read moreMarket cap
-
Turnover
-
Revenue
2.73M
EBIT %
-5,165.57 %
P/E
-
Dividend yield-%
-
Financial calendar
14.5
2025
General meeting '25
27.5
2025
Interim report Q1'24
27.8
2025
Interim report Q2'24
All
Press releases
ShowingAll content types
Oncoinvent ASA: Fourth Quarter 2024 Update and Results
ONCIN: Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools